Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults with Newly Diagnosed B Acute Lymphoblastic Leukemia
Inclusion Criteria
- REGISTRATION ELIGIBILITY CRITERIA (STEP 1)
- Newly diagnosed patients with CD-22 positive B-cell acute lymphoblastic leukemia (World Health Organization [WHO] criteria) are eligible; patients with Burkitt type ALL are NOT eligible
- Single-dose intrathecal cytarabine is allowed prior to registration or prior to initiation of systematic therapy for patient convenience; this is usually done at the time of the diagnostic bone marrow or venous line placement to avoid a second lumbar puncture; systemic chemotherapy must begin within 72 hours of this intrathecal therapy
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN), unless suspected leukemic involvement of the liver
- Direct bilirubin =< 3 x upper limit of normal (ULN), unless suspected leukemic involvement of the liver
- Calculated (calc.) creatinine clearance >= 50 mL/min by Cockcroft-Gault
- RANDOMIZATION ELIGIBILITY CRITERIA (STEP 2)
- Completion of remission induction therapy
- Patients with M2 marrow or better are eligible; patients with M3 or M4 marrow (greater than 25% lymphoblasts) will not be eligible to be randomized * Rating: M0, M1; Blast Cells (%): 0-5.0 * Rating: M2; Blast Cells (%): 5.1-25.0 * Rating: M3; Blast Cells (%): > 25.0-50.0 * Rating: M4; Blast Cells (%): > 50.0 * The term “blast cell” includes any cell that cannot be classified as a more mature normal element, and includes “leukemic cells,” pathologic lymphocytes, and stem cells
- Absolute neutrophil count (ANC) >= 750/mm^3
- Platelet count >= 75,000/mm^3
- Total bilirubin =< 1.5 x upper limit of normal (ULN), except for patients with known Gilbert’s syndrome
- AST =< 8 x upper limit of normal (ULN)
Exclusion Criteria
- Patients who have BCR-ABL fusion transcript determined by fluorescence in situ hybridization (FISH) or real time-polymerase chain reaction (RT-PCR) or t(9;22)(q34;q11) by cytogenetics are not eligible and should be considered for enrollment on studies that incorporate imatinib during induction; please note: patients must also be assessed for CD20 positivity and other markers; positivity for CD22 and CD20 is defined as baseline expression of the CD22 or CD20 antigen in more than 20% of leukemic cells using local multiparameter flow-cytometric immunophenotyping with the use of CD45 expression as a marker to gate the ALL blast population, according to recommendations from the European LeukemiaNet
- No prior therapy for ALL except for limited treatment (=< 7 days) with corticosteroids or hydroxyurea and a single dose of intrathecal cytarabine; however, patients who are being treated with chronic steroids for other reasons (for example, to treat asthma, autoimmune disorders, lupus, etc.) are eligible
- No prior therapy for acute leukemia except emergency therapy (corticosteroids or hydroxyurea) for blast cell crisis, superior vena cava syndrome, or renal failure due to leukemic infiltration of the kidneys; when indicated, leukapheresis or exchange transfusion is recommended to reduce the WBC
- Not pregnant and not nursing, because this study involves agents that have known genotoxic, mutagenic and teratogenic effects; therefore, for women of childbearing potential only, a negative urine or serum pregnancy test done =< 8 days prior to registration is required
- Patients with down syndrome are excluded from this study due to the likelihood of excessive toxicity resulting; these patients should be treated in consultation with a pediatric oncologist
Alabama
Birmingham
Alaska
Anchorage
Fairbanks
Arizona
Kingman
Phoenix
Scottsdale
Arkansas
Ft. Smith
California
Antioch
Arroyo Grande
Burbank
Clovis
Costa Mesa
Dublin
Fremont
Fresno
Modesto
Oakland
Orange
Palo Alto
Rancho Cordova
Redwood City
Richmond
Rohnert Park
Roseville
Sacramento
San Francisco
San Jose
San Leandro
San Rafael
Santa Clara
Santa Rosa
South San Francisco
Stockton
Vacaville
Vallejo
Walnut Creek
Colorado
Aurora
Boulder
Centennial
Denver
Englewood
Golden
Grand Junction
Greeley
Lafayette
Lakewood
Littleton
Lone Tree
Loveland
Thornton
Wheat Ridge
Connecticut
Hartford
New Haven
Florida
Fort Lauderdale
Hollywood
Miami
Orlando
Pembroke Pines
Georgia
Atlanta
Augusta
Hawaii
Aiea
Hilo
Honolulu
Lihue
Idaho
Boise
Caldwell
Coeur D'Alene
Emmett
Fruitland
Meridian
Nampa
Post Falls
Sandpoint
Twin Falls
Illinois
Alton
Burr Ridge
Chicago
Evanston
Glenview
Highland Park
Homer Glen
Lake Forest
Lisle
Maywood
Melrose Park
Mount Vernon
New Lenox
Orland Park
Iowa
Carroll
Des Moines
Fort Dodge
Iowa City
West Des Moines
Kansas
Garden City
Great Bend
Kansas City
Lawrence
Westwood
Wichita
Kentucky
Lexington
Louisiana
Baton Rouge
New Orleans
Maryland
Baltimore
Massachusetts
Boston
Michigan
Ann Arbor
Battle Creek
Brighton
Canton
Caro
Chelsea
Clarkston
Detroit
East China
Farmington Hills
Flint
Grand Rapids
Grosse Pointe Woods
Kalamazoo
Lansing
Livonia
Macomb Township
Marlette
Muskegon
Niles
Norton Shores
Pontiac
Reed City
Rochester Hills
Saginaw
Saint Joseph
Sterling Heights
Tawas City
Traverse City
Warren
West Branch
Wyoming
Ypsilanti
Minnesota
Aitkin
Brainerd
Burnsville
Cambridge
Coon Rapids
Deer River
Detroit Lakes
Duluth
Edina
Fergus Falls
Fosston
Fridley
Hibbing
Maple Grove
Maplewood
Minneapolis
Monticello
New Ulm
Park Rapids
Princeton
Robbinsdale
Rochester
Saint Louis Park
Saint Paul
Sandstone
Shakopee
Stillwater
Virginia
Waconia
Willmar
Woodbury
Wyoming
Missouri
Ballwin
Bolivar
Branson
Creve Coeur
Joplin
Rolla
Saint Joseph
Saint Louis
Saint Peters
Springfield
Washington
Montana
Anaconda
Billings
Bozeman
Butte
Great Falls
Kalispell
Missoula
Nebraska
Omaha
Nevada
Carson City
Henderson
Las Vegas
Pahrump
Reno
New Mexico
Albuquerque
New York
Buffalo
Lake Success
Manhasset
New Hyde Park
New York
Oneida
Rochester
Stony Brook
Syracuse
North Carolina
Chapel Hill
Durham
Greenville
Winston-Salem
North Dakota
Fargo
Jamestown
Ohio
Cincinnati
Cleveland
Columbus
West Chester
Oklahoma
Oklahoma City
Oregon
Baker City
Bend
Clackamas
Coos Bay
Newberg
Ontario
Portland
Redmond
Pennsylvania
Allentown
Bethlehem
East Stroudsburg
Hazleton
Philadelphia
Pittsburgh
Rhode Island
Providence
South Carolina
Boiling Springs
Clinton
Columbia
Easley
Greenville
Greer
Seneca
Texas
Houston
Lubbock
Utah
American Fork
Cedar City
Logan
Murray
Ogden
Provo
Riverton
Saint George
Salt Lake City
Virginia
Fairfax
Falls Church
Richmond
Washington
Aberdeen
Bellevue
Bellingham
Centralia
Edmonds
Everett
Issaquah
Kennewick
Lacey
Longview
Port Townsend
Renton
Seattle
Sedro-Woolley
Shelton
Vancouver
Walla Walla
Yakima
Yelm
Wisconsin
Ashland
Hayward
Madison
Marshfield
Milwaukee
New Richmond
Spooner
Superior
Wyoming
Cheyenne
Cody
Sheridan
Alberta
Calgary
Manitoba
Winnipeg
Nova Scotia
Halifax
Ontario
Ottawa
Quebec
Montreal
PRIMARY OBJECTIVES:
I. To confirm tolerability of the combination regimen with the addition of inotuzumab ozogamicin to the pediatric-inspired regimen of cancer and leukemia group B (CALGB) 10403.
II. To determine whether the addition of inotuzumab ozogamicin significantly improves the event-free survival (EFS) in patients who achieve an induction response achieved with the pediatric-inspired regimen of CALGB 10403, without censoring for transplant. (Phase III)
SECONDARY OBJECTIVES:
I. To determine the impact of inotuzumab ozogamicin on disease-free (DFS) and overall survival (OS) in patients who achieve an induction response.
II. To determine whether the addition of inotuzumab ozogamicin significantly improves the event-free survival (EFS) in patients who achieve an induction response achieved with the pediatric-inspired regimen of CALGB 10403, with censoring for transplant.
III. To determine the impact of inotuzumab ozogamicin on minimal residual disease (MRD) and correlate this with the EFS, DFS and OS.
IV. To determine the prognosis based on patients’ low-density array (LDA) gene signature in terms of EFS, DFS, and OS after treatment with or without inotuzumab ozogamicin when added to the C10403 backbone regimen.
V. To evaluate the toxicity and tolerability of the addition of inotuzumab ozogamicin to the pediatric-inspired regimen of CALGB 10403.
CORRELATIVE SCIENCE OBJECTIVES:
I. To assess both the correlation of MRD post-induction and at sequential time points with LDA signature.
II. To evaluate the influence of MRD status (detectable versus [vs.] not and as a continuous measure) in relation to EFS both in the univariate setting as well as adjusting for other clinical features including initial white blood cell (WBC), ethnicity, gender and age at diagnosis.
III. To evaluate the impact of inotuzumab ozogamicin (inotuzumab) on the kinetics of MRD during treatment with inotuzumab in patients randomized to the experimental treatment arm.
IV. To perform genomic analyses to identify and evaluate the incidence and clinical significance of recurring novel fusion genes including those associated with the BCR-ABL1-like signature and to correlate with MRD status, complete response (CR) rate, EFS and OS.
V. To assess whether rs4958351 is correlated with L-asp allergic reaction in the adolescent and young adult (AYA) population.
VI. To assess the incidence of inherited genetic variants in the GR1A1, CEP72, CPA2, TPMT, NUDT15, GRIN3A, GRIK1, and other genes (which can be found using a whole genome association study [GWAS]), are correlated with increased rates of target toxicities including peripheral neuropathy, hepatotoxicity, pancreatitis, myelosuppression, neurotoxicity, thrombosis, and osteonecrosis, and correlate with treatment discontinuation and other clinical response parameters including CR rate, EFS, and OS.
VII. To evaluate asparaginase pharmacokinetics in adolescents and young adults, and investigate its correlation with toxicities and treatment outcomes.
VIII. To investigate the effect of anti-polyethylene glycol (PEG) and anti-agouti signaling protein (ASP) antibodies (PEG-ASP) on ASP enzyme activity.
IX. To measure adherence to oral 6 mercaptopurine (MP) and methotrexate in AYAs with acute lymphoblastic leukemia (ALL) and to examine sociodemographic and behavioral determinants of adherence.
X. To determine the impact of adherence on risk of relapse among AYAs with ALL.
XI. To correlate specific karyotype groups (normal or various primary and secondary chromosomal abnormalities) with clinical and laboratory parameters.
XII. To correlate specific karyotype groups with response rates, response duration, survival, and cure in patients treated on this protocol.
XIII. To correlate specific karyotype groups with MRD.
XIV. To determine karyotype changes at relapse and the influence of the type of change (or no change) in karyotype at relapse.
OUTLINE:
COURSE I (REMISSION INDUCTION THERAPY): All patients receive allopurinol orally (PO) once daily until peripheral blasts and extramedullary disease are reduced and cytarabine intrathecally (IT) over 1 minute on day 1. Patients also receive daunorubicin hydrochloride intravenously (IV) and vincristine sulfate IV on days 1, 8, 15 and 22, dexamethasone PO or IV twice daily (BID) on days 1-7 and 15-21, pegylated recombinant L-asparaginase erwinia chrysanthemi IV on day 4, 5, or 6, and methotrexate IT over 1 minute on days 8 and 29. Patients with central nervous system (CNS) 3 disease receive methotrexate IT over 1 minute also on days 15 and 22. All patients then undergo bone marrow aspirate and biopsy on day 29.
Patients with response to remission induction therapy are randomized to 1 of 2 arms. Patients with no response are omitted from the study.
ARM I:
COURSE II (REMISSION CONSOLIDATION CHEMOTHERAPY): Patients receive cyclophosphamide IV on days 1 and 29, cytarabine IV or SC on days 1-4, 8-11, 29-32, and 36-39, mercaptopurine PO on days 1-14 and 29-42, and vincristine sulfate IV on days 15, 22, 43, and 50. Patients also receive pegylated recombinant L- asparaginase erwinia chrysanthemi IV on days 15 and 43, and methotrexate IT on days 1, 8, 15, and 22. Patients with CNS3 receive methotrexate IT only on days 1 and 8. CD20 positive (+) patients receive rituximab IV on days 1, 8, 29, and 36. Patients with evidence of testicular disease at diagnosis also receive radiation therapy (RT). Patients who are MRD+ and CD19+ after completion of this course receive dexamethasone IV or PO on day 1 and blinatumomab IV via continuous infusion on days 1-28, followed by a 14 day break. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo bone marrow aspirate and biopsy on day 56.
COURSE III (INTERIM MAINTENANCE CHEMOTHERAPY): Patients receive vincristine sulfate IV on days 1, 11, 21, 31, and 41, methotrexate IV and IT on days 1, 11, 21, 31, and 41, and pegylated recombinant L- asparaginase erwinia chrysanthemi IV on days 2 and 22. CD20+ patients receive rituximab IV on days 1 and 11.
COURSE IV (DELAYED INTENSIFICATION): Patients receive vincristine sulfate IV on days 1, 8, 15, 43, and 50, dexamethasone PO or IV BID on days 1-7 and 15-21, doxorubicin IV on days 1, 8, and 15, and pegylated recombinant L- asparaginase erwinia chrysanthemi IV on day 4, 5, or 6 and day 43. Patients also receive cyclophosphamide IV on day 29, cytarabine IV or SC on days 29-32 and 36-39, thioguanine PO on days 29-42 and methotrexate IT on days 1, 29, and 36. CD20+ patients receive rituximab IV on days 1 and 8. Patients then undergo bone marrow aspirate and biopsy one week after completion of course IV.
COURSE V (MAINTENANCE THERAPY): Patients receive vincristine sulfate IV on days 1, 29, and 57, dexamethasone PO or IV BID on days 1-5, 29-33, and 57-61, and mercaptopurine PO on days 1-84. Patients also receive methotrexate IT or PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78. Treatment repeats every 12 weeks for up to 3 years in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive inotuzumab ozogamicin IV on days 1, 8, and 15 and undergo bone marrow aspirate and biopsy on day 28. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients who are MRD+ and CD19+ after completion of 2 cycles of inotuzumab ozogamicin receive dexamethasone IV or PO on day 1 and blinatumomab IV via continuous infusion on days 1-28, followed by a 14 day break. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive remission consolidated chemotherapy, interim maintenance chemotherapy, delayed intensification, and maintenance therapy as in Arm I.
After completion of study treatment, patients are followed up every 2 months for 2 years, every 3 months for 2 years, and then every 6 months for up to 10 years.
Trial Phase Phase III
Trial Type Treatment
Lead Organization
Alliance for Clinical Trials in Oncology
Principal Investigator
Daniel Joseph DeAngelo
- Primary ID A041501
- Secondary IDs NCI-2016-01981
- Clinicaltrials.gov ID NCT03150693